Last reviewed · How we verify

Acute bacterial epiglottitis — Treatment Landscape & Competitive Intelligence

Acute bacterial epiglottitis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute bacterial epiglottitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Unasyn AMPICILLIN Bristol-Myers Squibb Penicillin-class Antibacterial Transient receptor potential cation channel subfamily M member 4 1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 1 drug in Acute bacterial epiglottitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute bacterial epiglottitis:

Cite this brief

Drug Landscape (2026). Acute bacterial epiglottitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-bacterial-epiglottitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing